China Cord Blood
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), China Cord Blood met expectations on revenue and met expectations on earnings per share.
Compared to the prior-year quarter, revenue increased and GAAP earnings per share increased significantly.
Gross margin increased, operating margin dropped, and net margin increased.
China Cord Blood logged revenue of $15.1 million. The one analyst polled by S&P Capital IQ expected sales of $15.0 million on the same basis. GAAP reported sales were 9.6% higher than the prior-year quarter's $13.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.06. The one earnings estimate compiled by S&P Capital IQ averaged $0.06 per share on the same basis. GAAP EPS of $0.09 for Q3 were 80% higher than the prior-year quarter's $0.05 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 77.1%, 30 basis points better than the prior-year quarter. Operating margin was 33.2%, 530 basis points worse than the prior-year quarter. Net margin was 41.6%, 1,300 basis points better than the prior-year quarter.
Next year's average estimate for revenue is $59.2 million. The average EPS estimate is $0.23.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 32 members out of 52 rating the stock outperform, and 20 members rating it underperform. Among 15 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), five give China Cord Blood a green thumbs-up, and 10 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on China Cord Blood is buy, with an average price target of $5.75.
Over the decades, small-cap stocks like China Cord Blood have provided market-beating returns, provided they're value-priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add China Cord Blood to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.